Cover Image
Market Research Report

Biologics Market Analysis By Source (Microbial, Mammalian), By Products (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy), By Disease Category, By Manufacturing, And Segment Forecasts, 2014 - 2025

Published by Grand View Research, Inc. Product code 490502
Published Content info 185 Pages
Delivery time: 1-2 business days
Price
Back to Top
Biologics Market Analysis By Source (Microbial, Mammalian), By Products (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy), By Disease Category, By Manufacturing, And Segment Forecasts, 2014 - 2025
Published: March 1, 2017 Content info: 185 Pages
Description

The global biologics market is anticipated to reach USD 399.5 billion by 2025, according to a new report by Grand View Research, Inc. Introduction of targeted therapies coupled with rising adoption of patient centric personalized medicine anticipated to fuel demand. Ever-increasing understanding of the cell physiology and stress, as well as the factors involved in protein production and heterologous gene expression have empowered the use of different living factories.

These living factories are the prokaryotic and eukaryotic cells. Enhancement of drug functionality through achieving successful protein folding and post-translational modifications is supportive for projected progress rate.

Moreover, rising adoption of biopharmaceuticals over chemically synthesized molecules is expected to propel revenue generation significantly. In addition to this, presence of several metabolic disorders that can be treated through the use of biologics is attributive to influence demand.

Combination of advanced bioengineering technologies for biopharmaceutical production is expected to boost progress in pharmaceutical industry. With recent advances in automation, the selection process can be done through high throughput screening (HTS) system for selection of viable clones.

Aforementioned method enables robust production of biopharmaceutical products by obtaining high-producing cell line. Advances with respect to upstream and downstream processing would directly translate into the growth in revenue for this market at a larger level.

However, development of biosimilars is expected to restrain the biologics year on year growth to certain extent. Although, the regulatory approval pathway for these products is not framed yet some drug manufacturers are opting to invest in the development of biobetters.

Further key findings from the report suggest:

  • Microbial expression systems dominated the market with respect to biopharmaceutical manufacturing
  • Presence of substantial number of products manufactured through the use of microbial sources can be attributed for largest share
  • Higher usage of monoclonal antibodies for the treatment of different diseases responsible for revenue generation
  • Moreover, pipeline drugs in the phase of development anticipated to bolster growth
  • Significant development pertaining to vaccines and increasing adoption anticipated to fuel progress
  • Oncology dominated over a decade and is expected to sustain its share over the forecast period.
  • Introduction of novel biologics with high efficacy coupled with the augmenting incidences of cancer is the vital impact rendering factor.
  • Substantial sales of biologics in the U.S. can be attributed for the largest share of North American market.
  • Established participants are implementing the manufacture of complex moieties in-house, which pronounces for the larger share of in-house manufacturing.
  • Asia Pacific is projected to showcase fastest growth in the coming years.
  • Increasing penetration of the biologics in the developing economies is expected to contribute in the projected growth.
  • Moreover, the university based projects implemented herein are attributive for the projected growth.
  • Key players contributing in this market are F Hoffman La Roche, Samsung Biologics, Celltrion, Pfizer Inc., Amgen, Novo Nordisk A/S, Sanofi, Abbvie Inc., Merck & Co. Inc, Addgene, Johnson & Johnson Services Inc., and Eli Lilly & Company.
  • These participants are investing in the hybrid business models through providing technology and service platforms.
  • Such milestones and royalties from partnered programs enables the cash flow generation which can be utilized in proprietary R&D.
Table of Contents
Product Code: GVR-1-68038-700-1

Table of Contents

Chapter 1. Research Methodology

  • 1.1. Information Procurement
  • 1.2. Data Analysis

Chapter 2. Executive Summary

Chapter 3. Biologics Market Variables, Trends & Scope

  • 3.1. Market Segmentation & Scope
    • 3.1.1. Market Driver Analysis
      • 3.1.1.1. Advancements in biomedical science
      • 3.1.1.2. Rise in biologics contract manufacturing services
      • 3.1.1.3. Several drugs going off patents
      • 3.1.1.4. Commercial success of biologics
    • 3.1.2. Market Restraint Analysis
      • 3.1.2.1. Pharmacokinetics challenges associated with biologics
      • 3.1.2.2. Rising control & cost for accessing biologics
      • 3.1.2.3. Development of biosimilars
  • 3.2. Penetration & Growth Prospect Mapping for Product, 2016
  • 3.3. Biologics -Swot Analysis, By Factor(Political & Legal, Economic And Technological)
  • 3.4. Industry Analysis-Porter's
  • 3.5. Biologics: Pipeline Analysis

Chapter 4. Biologics Market: Source Estimates & Trend Analysis

  • 4.1. Global Biologics Market: Source Movement Analysis
  • 4.2. Microbial Source
    • 4.2.1. Global microbial source market, 2014-2025(USD Billion)
  • 4.3. Mammalian Source
    • 4.3.1. Global mammalian source market, 2014-2025(USD Billion)
  • 4.4. Others
    • 4.4.1. Global other source market, 2014-2025(USD Billion)

Chapter 5. Biologics Market: Product Estimates & Trend Analysis

  • 5.1. Global Biologics Market: Product Movement Analysis
  • 5.2. Monoclonal Antibodies
    • 5.2.1. Global monoclonal antibodies market, 2014-2025(USD Billion)
    • 5.2.2. Monoclonal antibodies by application
      • 5.2.2.1. Diagnostic monoclonal antibodies
      • 5.2.2.1.1. Diagnostic MABs market, 2014-2025(USD Billion)
      • 5.2.2.1.2. Diagnostic MABs for biochemical analysis
      • 5.2.2.1.3. Diagnostic MABs for imaging
      • 5.2.2.2. Therapeutic MABs
      • 5.2.2.2.1. Therapeutic MABs market, 2014-2025(USD Billion)
      • 5.2.2.2.2. Direct MABs
      • 5.2.2.2.3. Targeting MABs
      • 5.2.2.3. Protein purification MABs
      • 5.2.2.3.1. Protein purification MABs market, 2014-2025(USD Billion)
      • 5.2.2.4. Other MABs
      • 5.2.2.4.1. Other MABs market, 2014-2025(USD Billion)
    • 5.2.3. Monoclonal antibodies by type
      • 5.2.3.1. Murine MABs
      • 5.2.3.1.1. Murine MABs market, 2014-2025(USD Billion)
      • 5.2.3.2. Chimeric MABs
      • 5.2.3.2.1. Chimeric MABs market, 2014-2025(USD Billion)
      • 5.2.3.3. Humanized MABs
      • 5.2.3.3.1. Humanized MABs market, 2014-2025(USD Billion)
      • 5.2.3.4. Human MABs
      • 5.2.3.4.1. Human MABs market, 2014-2025(USD Billion)
      • 5.2.3.5. Other MABs
      • 5.2.3.5.1. Other MABs market, 2014-2025(USD Billion)
  • 5.3. Vaccines
    • 5.3.1. Global vaccines market, 2014-2025(USD Billion)
  • 5.4. Recombinant Proteins
    • 5.4.1. Global recombinant proteins market, 2014-2025(USD Billion)
  • 5.5. Antisense, RNAi & Molecular Therapy
    • 5.5.1. Global antisense, RNAi & molecular therapy market, 2014-2025(USD Billion)
  • 5.6. Others
    • 5.6.1. Global other product market, 2014-2025(USD Billion)

Chapter 6. Biologics Market: Manufacturing Estimates & Trend Analysis

  • 6.1. Global Biologics Market: Manufacturing Movement Analysis
  • 6.2. Outsourced
    • 6.2.1. Global outsourced market, 2014-2025(USD Billion)
  • 6.3. In-house
    • 6.3.1. Global in-house market, 2014-2025(USD Billion)

Chapter 7. Biologics Market: Disease Category Estimates & Trend Analysis

  • 7.1. Global Biologics Market: Disease Category Movement Analysis
  • 7.2. Oncology
    • 7.2.1. Global oncology market, 2014-2025(USD Billion)
    • 7.2.2. MABs market for oncology
      • 7.2.2.1. Global MABs market for oncology, 2014-2025(USD Billion)
    • 7.2.3. Vaccines market for oncology
      • 7.2.3.1. Global vaccines market for oncology, 2014-2025(USD Billion)
    • 7.2.4. Recombinant proteins market for oncology
      • 7.2.4.1. Global recombinant proteins market for oncology, 2014-2025(USD Billion)
    • 7.2.5. Antisense, RNAi, & molecular therapy market for oncology
      • 7.2.5.1. Global antisense, RNAi, & molecular therapy market for oncology, 2014-2025(USD Billion)
    • 7.2.6. Other products market for oncology
      • 7.2.6.1. Global products market for oncology, 2014-2025(USD Billion)
  • 7.3. Infectious Disease
    • 7.3.1. Global infectious disease market, 2014-2025(USD Billion)
    • 7.3.2. Vaccines market for infectious disease
      • 7.3.2.1. Global vaccines market for infectious disease, 2014-2025(USD Billion)
    • 7.3.3. MABs market for infectious disease
      • 7.3.3.1. Global MABs market for infectious disease, 2014-2025(USD Billion)
    • 7.3.4. Antisense, RNAi, & molecular therapy market for infectious disease
      • 7.3.4.1. Global antisense, RNAi, & molecular therapy market for infectious disease, 2014-2025(USD Billion)
    • 7.3.5. Recombinant proteins market for infectious disease
      • 7.3.5.1. Global recombinant proteins market for infectious disease, 2014-2025(USD Billion)
    • 7.3.6. Other products market for infectious disease
      • 7.3.6.1. Global products market for infectious disease, 2014-2025(USD Billion)
  • 7.4. Immunological Disorders
    • 7.4.1. Global immunological disorders market, 2014-2025(USD Billion)
  • 7.5. Cardiovascular disorders
    • 7.5.1. Global cardiovascular disorders market, 2014-2025(USD Billion)
  • 7.6. Hematologic Disorders
    • 7.6.1. Global hematologic disorders market, 2014-2025(USD Billion)
  • 7.7. Others
    • 7.7.1. Global other indications market, 2014-2025(USD Billion)

Chapter 8. Biologics Market: Regional Estimates & Trend Analysis, by Source, Product, Manufacturing, & Disease Category

  • 8.1. Biologics Market Share By Region, 2015 & 2025
  • 8.2. North America
    • 8.2.1. North America biologics market, 2014-2025(USD Billion)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. biologics market, 2014-2025(USD Billion)
    • 8.2.3. Canada
      • 8.2.3.1. Canada biologics market, 2014-2025(USD Billion)
  • 8.3. Europe
    • 8.3.1. Europe biologics market, 2014-2025(USD Billion)
    • 8.3.2. Germany
      • 8.3.2.1. Germany biologics market, 2014-2025(USD Billion)
    • 8.3.3. UK
      • 8.3.3.1. UK biologics market, 2014-2025(USD Billion)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific biologics market, 2014-2025(USD Billion)
    • 8.4.2. Japan
      • 8.4.2.1. Japan biologics market, 2014-2025(USD Billion)
    • 8.4.3. China
      • 8.4.3.1. China biologics market, 2014-2025(USD Billion)
  • 8.5. Latin America
    • 8.5.1. Latin America biologics market, 2014-2025(USD Billion)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil biologics market, 2014-2025(USD Billion)
  • 8.6. Middle East & Africa(MEA)
    • 8.6.1. Middle East & Africa biologics market, 2014-2025(USD Billion)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa biologics market, 2014-2025(USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Strategy Framework
  • 9.2. Market Participation Categorization
  • 9.3. Company Profiles
    • 9.3.1. Samsung BioLogics
      • 9.3.1.1. Company overview
      • 9.3.1.2. Financial performance
      • 9.3.1.3. Product benchmarking
      • 9.3.1.4. Strategic initiatives
    • 9.3.2. Amgen
      • 9.3.2.1. Company overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Product benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. Novo Nordisk A/S
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Product benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. AbbVie Inc.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Sanofi
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Johnson & Johnson Services, Inc
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Pfizer Inc.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Merck & Co., Inc.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
    • 9.3.9. GSK group of companies
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Celltrion
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Precision Biologics, Inc.
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Merck KGaA
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Eli Lilly and Company
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
    • 9.3.14. Novartis AG
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Product benchmarking
      • 9.3.14.4. Strategic initiatives
    • 9.3.15. Bayer AG
      • 9.3.15.1. Company overview
      • 9.3.15.2. Financial performance
      • 9.3.15.3. Product benchmarking
      • 9.3.15.4. Strategic initiatives
    • 9.3.16. F. Hoffmann-La Roche Ltd
      • 9.3.16.1. Company overview
      • 9.3.16.2. Financial performance
      • 9.3.16.3. Product benchmarking
      • 9.3.16.4. Strategic initiatives
    • 9.3.17. AstraZeneca
      • 9.3.17.1. Company overview
      • 9.3.17.2. Financial performance
      • 9.3.17.3. Product benchmarking
      • 9.3.17.4. Strategic initiatives

List of Tables

  • TABLE 1: North America biologics market estimates& forecasts, by source, 2014 - 2025 (USD Billion)
  • TABLE 2: North America biologics market estimates& forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 3: North America monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 4: North America diagnostic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 5: North America therapeutic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 6: North America monoclonal antibodies market estimates & forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 7: North America biologics market estimates & forecasts, by manufacturing, 2014 - 2025 (USD Billion)
  • TABLE 8: North America biologics market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Billion)
  • TABLE 9: North America oncology biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 10: North America infectious diseases biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 11: U.S. biologics market estimates& forecasts, by source, 2014 - 2025 (USD Billion)
  • TABLE 12: U.S. biologics market estimates& forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 13: U.S. monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 14: U.S. diagnostic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 15: U.S. therapeutic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 16: U.S. monoclonal antibodies market estimates & forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 17: U.S. biologics market estimates & forecasts, by manufacturing, 2014 - 2025 (USD Billion)
  • TABLE 18: U.S. biologics market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Billion)
  • TABLE 19: U.S. oncology biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 20: U.S. infectious diseases biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 21: Canada biologics market estimates& forecasts, by source, 2014 - 2025 (USD Billion)
  • TABLE 22: Canada biologics market estimates& forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 23: Canada monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 24: Canada diagnostic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 25: Canada therapeutic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 26: Canada monoclonal antibodies market estimates & forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 27: Canada biologics market estimates & forecasts, by manufacturing, 2014 - 2025 (USD Billion)
  • TABLE 28: Canada biologics market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Billion)
  • TABLE 29: Canada oncology biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 30: Canada infectious diseases biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 31: Europe biologics market estimates& forecasts, by source, 2014 - 2025 (USD Billion)
  • TABLE 32: Europe biologics market estimates& forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 33: Europe monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 34: Europe diagnostic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 35: Europe therapeutic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 36: Europe monoclonal antibodies market estimates & forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 37: Europe biologics market estimates & forecasts, by manufacturing, 2014 - 2025 (USD Billion)
  • TABLE 38: Europe biologics market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Billion)
  • TABLE 39: Europe oncology biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 40: Europe infectious diseases biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 41: Germany biologics market estimates& forecasts, by source, 2014 - 2025 (USD Billion)
  • TABLE 42: Germany biologics market estimates& forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 43: Germany monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 44: Germany diagnostic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 45: Germany therapeutic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 46: Germany monoclonal antibodies market estimates & forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 47: Germany biologics market estimates & forecasts, by manufacturing, 2014 - 2025 (USD Billion)
  • TABLE 48: Germany biologics market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Billion)
  • TABLE 49: Germany oncology biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 50: Germany infectious diseases biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 51: UK biologics market estimates& forecasts, by source, 2014 - 2025 (USD Billion)
  • TABLE 52: UK biologics market estimates& forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 53: UK monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 54: UK diagnostic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 55: UK therapeutic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 56: UK monoclonal antibodies market estimates & forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 57: UK biologics market estimates & forecasts, by manufacturing, 2014 - 2025 (USD Billion)
  • TABLE 58: UK biologics market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Billion)
  • TABLE 59: UK oncology biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 60: UK infectious diseases biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 61: Asia Pacific biologics market estimates& forecasts, by source, 2014 - 2025 (USD Billion)
  • TABLE 62: Asia Pacific biologics market estimates& forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 63: Asia Pacific monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 64: Asia Pacific diagnostic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 65: Asia Pacific therapeutic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 66: Asia Pacific monoclonal antibodies market estimates & forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 67: Asia Pacific biologics market estimates & forecasts, by manufacturing, 2014 - 2025 (USD Billion)
  • TABLE 68: Asia Pacific biologics market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Billion)
  • TABLE 69: Asia Pacific oncology biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 70: Asia Pacific infectious diseases biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 71: Japan biologics market estimates& forecasts, by source, 2014 - 2025 (USD Billion)
  • TABLE 72: Japan biologics market estimates& forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 73: Japan monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 74: Japan diagnostic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 75: Japan therapeutic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 76: Japan monoclonal antibodies market estimates & forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 77: Japan biologics market estimates & forecasts, by manufacturing, 2014 - 2025 (USD Billion)
  • TABLE 78: Japan biologics market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Billion)
  • TABLE 79: Japan oncology biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 80: Japan infectious diseases biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 81: China biologics market estimates& forecasts, by source, 2014 - 2025 (USD Billion)
  • TABLE 82: China biologics market estimates& forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 83: China monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 84: China diagnostic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 85: China therapeutic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 86: China monoclonal antibodies market estimates & forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 87: China biologics market estimates & forecasts, by manufacturing, 2014 - 2025 (USD Billion)
  • TABLE 88: China biologics market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Billion)
  • TABLE 89: China oncology biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 90: China infectious diseases biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 91: Latin America biologics market estimates & forecasts, by source, 2014 - 2025 (USD Billion)
  • TABLE 92: Latin America biologics market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 93: Latin America monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 94: Latin America diagnostic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 95: Latin America therapeutic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 96: Latin America monoclonal antibodies market estimates & forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 97: Latin America biologics market estimates & forecasts, by manufacturing, 2014 - 2025 (USD Billion)
  • TABLE 98: Latin America biologics market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Billion)
  • TABLE 99: Latin America oncology biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 100: Latin America infectious diseases biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 101: Brazil biologics market estimates& forecasts, by source, 2014 - 2025 (USD Billion)
  • TABLE 102: Brazil biologics market estimates& forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 103: Brazil monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 104: Brazil diagnostic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 105: Brazil therapeutic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 106: Brazil monoclonal antibodies market estimates & forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 107: Brazil biologics market estimates & forecasts, by manufacturing, 2014 - 2025 (USD Billion)
  • TABLE 108: Brazil biologics market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Billion)
  • TABLE 109: Brazil oncology biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 110: Brazil infectious diseases biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 111: MEA biologics market estimates& forecasts, by source, 2014 - 2025 (USD Billion)
  • TABLE 112: MEA biologics market estimates& forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 113: MEA monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 114: MEA diagnostic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 115: MEA therapeutic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 116: MEA monoclonal antibodies market estimates & forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 117: MEA biologics market estimates & forecasts, by manufacturing, 2014 - 2025 (USD Billion)
  • TABLE 118: MEA biologics market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Billion)
  • TABLE 119: MEA oncology biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 120: MEA infectious diseases biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 121: South Africa biologics market estimates& forecasts, by source, 2014 - 2025 (USD Billion)
  • TABLE 122: South Africa biologics market estimates& forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 123: South Africa monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 124: South Africa diagnostic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 125: South Africa therapeutic monoclonal antibodies market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 126: South Africa monoclonal antibodies market estimates & forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 127: South Africa biologics market estimates & forecasts, by manufacturing, 2014 - 2025 (USD Billion)
  • TABLE 128: South Africa biologics market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Billion)
  • TABLE 129: South Africa oncology biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)
  • TABLE 130: South Africa infectious diseases biologics market estimates & forecasts, by products, 2014 - 2025 (USD Billion)

List of Figures

  • FIG. 1: Market research process
  • FIG. 2: Information Procurement
  • FIG. 3: Primary research pattern
  • FIG. 4: Market research approaches
  • FIG. 5: Value chain based sizing & forecasting
  • FIG. 6: QFD modelling for market share assessment
  • FIG. 7: Market summary
  • FIG. 8: Market trends & outlook
  • FIG. 9: Market segmentation & scope
  • FIG. 10: Market driver relevance analysis (Current & future impact)
  • FIG. 11: Market restraint relevance analysis (Current & future impact)
  • FIG. 12: Penetration & growth prospect mapping for Product, 2016
  • FIG. 13: SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 14: Porter's Five Forces Analysis
  • FIG. 15: Global biologics market: Source outlook key takeaways
  • FIG. 16: Global biologics market: Source movement analysis
  • FIG. 17: Global microbial source market, 2014 - 2025 (USD Billion)
  • FIG. 18: Global mammalian source market, 2014 - 2025 (USD Billion)
  • FIG. 19: Global other source market, 2014 - 2025 (USD Billion)
  • FIG. 20: Global biologics market: Product outlook key takeaways
  • FIG. 21: Global biologics market: Product movement analysis
  • FIG. 22: Global monoclonal antibodies market, 2014 - 2025 (USD Billion)
  • FIG. 23: Global diagnostic MABs market, 2014 - 2025 (USD Billion)
  • FIG. 24: Global diagnostic MABs for biochemical analysis market, 2014 - 2025 (USD Billion)
  • FIG. 25: Global diagnostic MABs for imaging market, 2014 - 2025 (USD Billion)
  • FIG. 26: Global therapeutic MABs market, 2014 - 2025 (USD Billion)
  • FIG. 27: Global direct MABs market, 2014 - 2025 (USD Billion)
  • FIG. 28: Global targeting MABs market, 2014 - 2025 (USD Billion)
  • FIG. 29: Global protein purification MABs market, 2014 - 2025 (USD Billion)
  • FIG. 30: Other MABs market, 2014 - 2025 (USD Billion)
  • FIG. 31: Global murine MABs market, 2014 - 2025 (USD Billion)
  • FIG. 32: Global chimeric MABs market, 2014 - 2025 (USD Billion)
  • FIG. 33: Global humanized MABs market, 2014 - 2025 (USD Billion)
  • FIG. 34: Global human MABs market, 2014 - 2025 (USD Billion)
  • FIG. 35: Global other MABs market, 2014 - 2025 (USD Billion)
  • FIG. 36: Global vaccines market, 2014 - 2025 (USD Billion)
  • FIG. 37: Global recombinant proteins market, 2014 - 2025 (USD Billion)
  • FIG. 38: Global antisense, RNAi & molecular therapy market, 2014 - 2025 (USD Billion)
  • FIG. 39: Global other product market, 2014 - 2025 (USD Billion)
  • FIG. 40: Global biologics market: Manufacturing outlook key takeaways
  • FIG. 41: Global biologics market: Manufacturing movement analysis
  • FIG. 42: Global outsourced market, 2014 - 2025 (USD Billion)
  • FIG. 43: Global in-house market, 2014 - 2025 (USD Billion)
  • FIG. 44: Global biologics market: Disease category outlook key takeaways
  • FIG. 45: Global biologics market: Disease category movement analysis
  • FIG. 46: Global oncology market, 2014 - 2025 (USD Billion)
  • FIG. 47: Global infectious disease market, 2014 - 2025 (USD Billion)
  • FIG. 48: Global immunological disorders market, 2014 - 2025 (USD Billion)
  • FIG. 49: Global cardiovascular disorders market, 2014 - 2025 (USD Billion)
  • FIG. 50: Global hematologic disorders market, 2014 - 2025 (USD Billion)
  • FIG. 51: Global other indications market, 2014 - 2025 (USD Billion)
  • FIG. 52: Regional market place: Key takeaway
  • FIG. 53: Biologics regional outlook, 2016 & 2025
  • FIG. 54: North America biologics market, 2014 - 2025 (USD Billion)
  • FIG. 55: U.S. biologics market, 2014 - 2025 (USD Billion)
  • FIG. 56: Canada biologics market, 2014 - 2025 (USD Billion)
  • FIG. 57: Europe biologics market, 2014 - 2025 (USD Billion)
  • FIG. 58: Germany biologics market, 2014 - 2025 (USD Billion)
  • FIG. 59: UK biologics market, 2014 - 2025 (USD Billion)
  • FIG. 60: Asia Pacific biologics market, 2014 - 2025 (USD Billion)
  • FIG. 61: Japan biologics market, 2014 - 2025 (USD Billion)
  • FIG. 62: China biologics market, 2014 - 2025 (USD Billion)
  • FIG. 63: Latin America biologics market, 2014 - 2025 (USD Billion)
  • FIG. 64: Brazil biologics market, 2014 - 2025 (USD Billion)
  • FIG. 65: Middle East & Africa biologics market, 2014 - 2025 (USD Billion)
  • FIG. 66: South Africa biologics market, 2014 - 2025 (USD Billion)
  • FIG. 67: Strategy framework
  • FIG. 68: Participant categorization
Back to Top